EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types

Jeanne Shen iD, Yoon-La Choi, Taebum Lee, Hyojin Kim, Young Kwang Chae, Ben W Dulken, Stephanie Bogdan, Maggie Huang, George A Fisher, Sehhoon Park iD, Se-Hoon Lee, Jun-Eul Hwang und 18 weitere

Journal for ImmunoTherapy of Cancer · 2024-02 · 12 (2) · e008339

DOI: 10.1136/jitc-2023-008339 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 14.02.2024. Verfasst von Jeanne Shen und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Stanford University School of Medicine, Stanford, California, USA jeannes@stanford.edu ock.chanyoung@lunit.io. Hauptthemen laut MEDLINE: Artificial Intelligence, Brain Neoplasms. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, the National Cancer Institute (NCI), National Institutes of Health, Lunit Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The inflamed immune phenotype (IIP), defined by enrichment of tumor-infiltrating lymphocytes (TILs) within intratumoral areas, is a promising tumor-agnostic biomarker of response to immune checkpoint inhibitor (ICI) therapy. However, it is challenging to define the IIP in an objective and reproducible manner during manual histopathologic examination. Here, we investigate artificial intelligence (AI)-based immune phenotypes capable of predicting ICI clinical outcomes in multiple solid tumor types.

Methods

Lunit SCOPE IO is a deep learning model which determines the immune phenotype of the tumor microenvironment based on TIL analysis. We evaluated the correlation between the IIP and ICI treatment outcomes in terms of objective response rates (ORR), progression-free survival (PFS), and overall survival (OS) in a cohort of 1,806 ICI-treated patients representing over 27 solid tumor types retrospectively collected from multiple institutions.

Results

We observed an overall IIP prevalence of 35.2% and significantly more favorable ORRs (26.3% vs 15.8%), PFS (median 5.3 vs 3.1 months, HR 0.68, 95% CI 0.61 to 0.76), and OS (median 25.3 vs 13.6 months, HR 0.66, 95% CI 0.57 to 0.75) after ICI therapy in IIP compared with non-IIP patients, respectively (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Artificial IntelligenceBrain NeoplasmsHumansImmune Checkpoint InhibitorsRetrospective StudiesBiomarkers, TumorPhenotypeTumor Microenvironment

Stichwörter der Autor:innen

Immune Checkpoint InhibitorsLymphocytes, Tumor-InfiltratingTumor Biomarkers

Substanzen

Immune Checkpoint InhibitorsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, Stanford University School of Medicine, Stanford, California, USA jeannes@stanford.edu ock.chanyoung@lunit.io.
  • Center for Artificial Intelligence in Medicine & Imaging, Stanford University, Stanford, California, USA.
  • Department of Pathology and Translational Genomics, Sungkyunkwan University School of Medicine, Suwon, Korea (the Republic of).
  • Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Korea (the Republic of).
  • Department of Pathology, Chonnam National University Medical School, Gwangju, Korea (the Republic of).
  • Department of Pathology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea (the Republic of).

ORCID-Profile: Jeanne Shen, Sehhoon Park

Förderung

  • NCI NIH HHS
  • the National Cancer Institute (NCI), National Institutes of Health
  • Lunit Inc.

Zitieren

APA

Shen, J., Choi, Y. L., Lee, T., Kim, H., Chae, Y. K., Dulken, B. W., Bogdan, S., Huang, M., Fisher, G. A., Park, S., Lee, S. H., Hwang, J. E., Chung, J. H., Kim, L., Song, H., Pereira, S., Shin, S., Lim, Y., Ahn, C. H., …, & Ock, C. Y. (2024). Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types. Journal for ImmunoTherapy of Cancer, 12(2), e008339. https://doi.org/10.1136/jitc-2023-008339

Vancouver

Shen J, Choi YL, Lee T, Kim H, Chae YK, Dulken BW, et al. Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types. Journal for ImmunoTherapy of Cancer. 2024;12(2):e008339. doi:10.1136/jitc-2023-008339

BibTeX
@article{Shen2024,
  author = {Shen, Jeanne and Choi, Yoon-La and Lee, Taebum and Kim, Hyojin and Chae, Young Kwang and Dulken, Ben W and Bogdan, Stephanie and Huang, Maggie and Fisher, George A and Park, Sehhoon and Lee, Se-Hoon and Hwang, Jun-Eul and Chung, Jin-Haeng and Kim, Leeseul and Song, Heon and Pereira, Sergio and Shin, Seunghwan and Lim, Yoojoo and Ahn, Chang Ho and Kim, Seulki and Oum, Chiyoon and Kim, Sukjun and Park, Gahee and Song, Sanghoon and Jung, Wonkyung and Kim, Seokhwi and Bang, Yung-Jue and Mok, Tony S K and Ali, Siraj M and Ock, Chan-Young},
  title = {Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  volume = {12},
  number = {2},
  pages = {e008339},
  doi = {10.1136/jitc-2023-008339}
}
Kostenlos starten →